Chemokine Therapeutics Announces New President And Chief Executive Officer
4/16/2008
VANCOUVER, BRITISH COLUMBIA -- Apr 16, 2008 -- Chemokine Therapeutics Corp. ("Chemokine Therapeutics" or the "Company"), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular disease today announced the appointment of Walter Korz as its new President and Chief Executive Officer (CEO). Mr. Korz succeeds Bashir Jaffer who held the position as Chief Executive Officer on an interim basis since December 2007. Mr. Jaffer will continue to serve the Company as Chief Financial Officer.
"With approval from the FDA and Health Canada to conduct a Phase II study with our lead compound, CTCE-9908, I look forward to leading our management team efforts in raising capital and stimulating the growth of the Company as it continues through clinical development," said Walter Korz, President and CEO of the Company.
Mr. Korz has been with the Company since March 2003 serving as Vice President of Drug Development. His multi-disciplinary experience spans seventeen years in the biotechnology sector as well as an additional ten years in the healthcare sector. He brings with him a broad drug development background, including experience in regulatory, clinical, business development and medical affairs. His experience with therapeutic and diagnostic research drugs encompasses various indications including cancer, multiple sclerosis, rheumatoid arthritis, and psoriasis. Prior to joining Chemokine, from 2000 to 2003 he held the position of Clinical Development Manager with Angiotech Pharmaceuticals overseeing their systemic therapeutics. Mr. Korz's experience includes overseeing the development of diagnostic and therapeutic products with AltaRex Corp. in Edmonton and Boston. His initial drug development, clinical and regulatory experiences were gained with Biomira Inc.
The Company would like to thank Bashir Jaffer for his many contributions over the past four months in the position of Interim CEO and looks forward to his continued service as a core member of the management team.
About Chemokine Therapeutics Corp. (Toronto:CTI.TO - News)(OTC BB:CHKT.OB - News)
Chemokine Therapeutics is a product-focused biotechnology company developing drug candidates in the field of chemokines. Chemokines are a class of signaling proteins that play a critical role in the growth, differentiation, and maturation of cells necessary for fighting infection as well as tissue repair and regeneration. Chemokines also have an important role in cancer metastasis and growth. Chemokine Therapeutics is a leader in research in the field of chemokines and has several products in various stages of development.
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995: Statements in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements that involve risks and uncertainties, which may cause actual results to differ materially from the statements made. For this purpose, any statements that are contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "projects", and similar expressions are intended to identify forward-looking statements. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, those associated with the success of research and development programs, the Company's ability to raise additional funding and the potential dilutive effects thereof, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, reliance on subcontractors and key personnel and other risks detailed from time-to-time in the Company's public disclosure documents and other filings with the U.S. Securities and Exchange Commission and Canadian securities regulatory authorities. Forward-looking statements are made as of the date hereof, and the Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.